Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study
Merck Sharp & Dohme LLC
Jason J Luke; Paolo A Ascierto; Muhammad A Khattak; Luis de la Cruz Merino; Michele Del Vecchio; Piotr Rutkowski; Francesco Spagnolo; Jacek Mackiewicz; Vanna Chiarion-Sileni; John M Kirkwood; Caroline Robert; Jean-Jacques Grob; Federica de Galitiis; Dirk Schadendorf; Matteo S Carlino; Xi Lawrence Wu; Mizuho Fukunaga-Kalabis; Clemens Krepler; Alexander M M Eggermont; Georgina V Long